Re: Rano Matta, Refik Saskin, Sarah Neu, et al. Predicting mirabegron treatment response in patients with overactive bladder: a post hoc analysis of data from clinical trials. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.04.001

We read with interest the article by Matta et al. on predicting the response to mirabegron in patients with overactive bladder (OAB). Mirabegron is a selective agonist of β3-adrenoceptors on detrusor muscle that facilitates filling of the bladder and storage of urine without modifying voiding function. Overall, the incidence of adverse events is rare (the main side effect is hypertension) and mirabegron is generally well tolerated. The authors conducted this study with the aim of developing a tool for predicting treatment response and ultimately increasing patient adherence to therapy with mirabegron. We would like to make a few observations regarding the methodology and results.